Target intelligence / Profile preview

TBC1 domain family member 32 (TBC1D32)

Target
TBC1D32
Molecular classification
Other (TBC domain-containing protein; not an enzyme, transporter, receptor, or classical signaling protein; specifically, a ciliary protein involved in ciliary assembly and signaling)
01

Overview

TBC1 domain family member 32 (TBC1D32), also known as BROMI or protein broad-minded, is a protein encoded by the TBC1D32 gene and is required for high-level Sonic Hedgehog (Shh) pathway activity during neural development[3]. It is a key regulator of cilium structure and function, acting through its interaction with CDK20 to ensure proper assembly of the ciliary axoneme and membrane, processes that are necessary for the activation of GLI2 in Shh signaling[3]. TBC1D32 is classified as a ciliopathy-associated protein, and mutations in this gene are responsible for a severe, autosomal recessive phenotype involving congenital hypopituitarism, midline developmental brain anomalies, craniofacial dysmorphism, limb defects (such as polydactyly), cleft palate, and other syndromic features seen in orofacial digital syndromes[1][2][3]. Primary cilium dysfunction caused by TBC1D32 loss-of-function variants leads to highly variable, often severe congenital disorders diagnosed as ciliopathies, contributing to pituitary development disorders and associated hormone deficiencies[1][2]. There are no known drugs that directly interact with TBC1D32, and it is not currently considered a druggable therapeutic target.

Other names
Protein broad-mindedBROMIC6orf170C6orf171FLJ30899dJ310J6.1FLJ34235bA57L9.1RP100protein broad-mindedbroad-minded homolog
02

Biological functions

Cilium assemblySonic Hedgehog (Shh) signalingBrain developmentProtein-protein interactions (including with enzymes and GTPases)Cell cycle regulationIntracellular protein transport
03

Disease associations

CiliopathyHypopituitarismOrofacial digital syndromesDevelopmental disorders (including congenital anomalies of the brain, face, and extremities)
04

Safety considerations

Not applicable (no direct drugs or therapeutics known to target TBC1D32)

Beyond the preview

Go deeper on TBC1 domain family member 32 (TBC1D32).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBC1 domain family member 32 (TBC1D32).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call